Cargando…
Bronchodilator efficacy of 18 μg once-daily tiotropium inhalation via Discair(®) versus HandiHaler(®) in adults with chronic obstructive pulmonary disease: randomized, active-controlled, parallel-group, open-label, Phase IV trial
PURPOSE: To compare the bronchodilator efficacy of 18 μg once-daily tiotropium inhalation administered via Discair(®) versus HandiHaler(®) in adults with moderate-to-severe chronic obstructive pulmonary disease (COPD). PATIENTS AND METHODS: Fifty-eight patients with moderate-to-severe COPD were enro...
Autores principales: | Yildiz, Pinar, Bayraktaroglu, Mesut, Gorgun, Didem, Secik, Funda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125983/ https://www.ncbi.nlm.nih.gov/pubmed/27920513 http://dx.doi.org/10.2147/COPD.S119114 |
Ejemplares similares
-
Tiotropium Respimat(®) Versus HandiHaler(®): Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials
por: Calverley, Peter M. A., et al.
Publicado: (2016) -
Tiotropium HandiHaler(®) in the treatment of COPD: A safety review
por: Kesten, Steven, et al.
Publicado: (2009) -
Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis
por: Halpin, David MG, et al.
Publicado: (2015) -
Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial
por: Dahl, Ronald, et al.
Publicado: (2015) -
Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat(®) or HandiHaler(®)
por: Dekhuijzen, Pieter Nicolaas Richard, et al.
Publicado: (2016)